Cardiovascular toxicity of illicit anabolic-androgenic steroid use
Long-term AAS use was associated with myocardial dysfunction and coronary atherosclerosis.
Observational; exposure self-selected.
Original source ↗Loading TrenasCycles…
TrenasCycles
Loading TrenasCycles…
Designer anabolic steroid
methyltren
Methyltrienolone is discussed as an extremely potent strength-and-muscle drug. Also called R1881, it is actually best characterized as a laboratory androgen, not a tested bodybuilding medicine. Receptor potency does not tell us how much size or strength a person would gain. Liver injury and an unknown human safety margin are the main concerns.
Human-tissue binding studies confirm high-affinity androgen-receptor activity, but controlled human efficacy and safety trials are absent. Hepatic risk is inferred from its oral 17-alpha-alkylated structure and the AAS liver-injury literature.
Potentially severe cholestatic liver injury, adverse lipids, gonadal suppression, androgenic/behavioral effects and cardiovascular harm; true human dose-risk is unknown.
Liver panel and symptoms of jaundice; HDL/LDL/triglycerides; blood pressure; CBC; reproductive hormones. Testing cannot establish a safe exposure.
Never approved for human use. It is mainly a laboratory reference androgen, not a medicine.
Other aliases: methyltren · metribolone · MTren · R1881
Long-term AAS use was associated with myocardial dysfunction and coronary atherosclerosis.
Observational; exposure self-selected.
Original source ↗AAS use was associated with increased cardiovascular-disease outcomes.
Observational; residual confounding possible.
Original source ↗Confirmed high-affinity androgen-receptor binding.
Laboratory tissue study; no clinical safety or performance outcomes.
Original source ↗Reviews cholestasis, peliosis and hepatic tumors associated with AAS, especially oral 17-alpha-alkylated agents.
Class-level evidence; cannot quantify each designer steroid's risk.
Original source ↗